JP7523450B2 - アミノ酸化合物およびその使用方法 - Google Patents

アミノ酸化合物およびその使用方法 Download PDF

Info

Publication number
JP7523450B2
JP7523450B2 JP2021544112A JP2021544112A JP7523450B2 JP 7523450 B2 JP7523450 B2 JP 7523450B2 JP 2021544112 A JP2021544112 A JP 2021544112A JP 2021544112 A JP2021544112 A JP 2021544112A JP 7523450 B2 JP7523450 B2 JP 7523450B2
Authority
JP
Japan
Prior art keywords
tetrahydro
naphthyridin
homoserine
ethyl
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021544112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508657A (ja
JP2022508657A5 (enExample
Inventor
ジェイコブ・チャ
マヌエル・ムニョス
モーリーン・ライリー
ニコール・クーパー
カテリーナ・レフテリス
デイビッド・ジェイ・モーガンズ・ジュニア
ティモシー・ホム
ヤジュン・ジェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliant Therapeutics Inc
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of JP2022508657A publication Critical patent/JP2022508657A/ja
Publication of JP2022508657A5 publication Critical patent/JP2022508657A5/ja
Application granted granted Critical
Publication of JP7523450B2 publication Critical patent/JP7523450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021544112A 2018-10-08 2019-10-08 アミノ酸化合物およびその使用方法 Active JP7523450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862742901P 2018-10-08 2018-10-08
US62/742,901 2018-10-08
PCT/US2019/055252 WO2020076862A1 (en) 2018-10-08 2019-10-08 Amino acid compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2022508657A JP2022508657A (ja) 2022-01-19
JP2022508657A5 JP2022508657A5 (enExample) 2022-10-31
JP7523450B2 true JP7523450B2 (ja) 2024-07-26

Family

ID=70051340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544112A Active JP7523450B2 (ja) 2018-10-08 2019-10-08 アミノ酸化合物およびその使用方法

Country Status (23)

Country Link
US (3) US11180494B2 (enExample)
EP (1) EP3863711A4 (enExample)
JP (1) JP7523450B2 (enExample)
KR (1) KR20210101205A (enExample)
CN (1) CN113195053B (enExample)
AU (1) AU2019358041A1 (enExample)
BR (1) BR112021006620A2 (enExample)
CA (1) CA3115643A1 (enExample)
CL (2) CL2021000863A1 (enExample)
CO (1) CO2021004279A2 (enExample)
CR (1) CR20210224A (enExample)
CU (1) CU24690B1 (enExample)
DO (1) DOP2021000054A (enExample)
EA (1) EA202190967A1 (enExample)
EC (1) ECSP21032717A (enExample)
IL (1) IL282026A (enExample)
JO (1) JOP20210056A1 (enExample)
MX (1) MX2021004015A (enExample)
PE (1) PE20211463A1 (enExample)
PH (1) PH12021550784A1 (enExample)
SG (1) SG11202103283RA (enExample)
TW (1) TW202028179A (enExample)
WO (1) WO2020076862A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
TW202028179A (zh) * 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
TW202235417A (zh) 2020-11-19 2022-09-16 美商普萊恩醫療公司 整合素抑制劑及其用途
WO2024145245A2 (en) * 2022-12-27 2024-07-04 Pliant Therapeutics, Inc. Alpha-v-beta-8 integrin inhibitors and uses thereof
GB202301024D0 (en) * 2023-01-24 2023-03-08 Univ Bradford Compounds
CN122270455A (zh) * 2023-12-22 2026-06-23 北京炫景瑞医药科技有限公司 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010176A1 (en) 1997-12-17 2002-01-24 Askew Ben C. Integrin receptor antagonists
WO2016153054A1 (ja) 2015-03-25 2016-09-29 富士フイルム株式会社 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体
WO2018009501A1 (en) 2016-07-05 2018-01-11 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
WO2018089355A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
WO2018160522A1 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100037600A (ko) 2007-06-13 2010-04-09 브리스톨-마이어스 스큅 컴퍼니 응고 인자 억제제로서의 디펩티드 유사체
US20120289481A1 (en) * 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
US10538542B2 (en) 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
EP3843728B1 (en) 2018-08-29 2025-04-30 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) * 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS
KR20230049584A (ko) 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010176A1 (en) 1997-12-17 2002-01-24 Askew Ben C. Integrin receptor antagonists
WO2016153054A1 (ja) 2015-03-25 2016-09-29 富士フイルム株式会社 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体
WO2018009501A1 (en) 2016-07-05 2018-01-11 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
WO2018089355A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
WO2018160522A1 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin

Also Published As

Publication number Publication date
CA3115643A1 (en) 2020-04-16
CO2021004279A2 (es) 2021-04-30
AU2019358041A1 (en) 2021-05-20
US11952376B2 (en) 2024-04-09
US20200109141A1 (en) 2020-04-09
CL2021000863A1 (es) 2021-09-10
CN113195053B (zh) 2024-08-30
PH12021550784A1 (en) 2021-10-25
US20220144829A1 (en) 2022-05-12
EP3863711A4 (en) 2022-07-06
EP3863711A1 (en) 2021-08-18
CN113195053A (zh) 2021-07-30
SG11202103283RA (en) 2021-04-29
DOP2021000054A (es) 2021-08-31
MX2021004015A (es) 2021-06-23
IL282026A (en) 2021-05-31
WO2020076862A1 (en) 2020-04-16
JOP20210056A1 (ar) 2021-03-24
CL2023001331A1 (es) 2023-10-20
ECSP21032717A (es) 2021-06-30
KR20210101205A (ko) 2021-08-18
CU20210027A7 (es) 2021-11-04
US20240270742A1 (en) 2024-08-15
BR112021006620A2 (pt) 2021-07-06
TW202028179A (zh) 2020-08-01
EA202190967A1 (ru) 2021-09-17
JP2022508657A (ja) 2022-01-19
PE20211463A1 (es) 2021-08-05
CR20210224A (es) 2021-06-08
US11180494B2 (en) 2021-11-23
CU24690B1 (es) 2023-12-07

Similar Documents

Publication Publication Date Title
US20240270742A1 (en) Substituted amino acids as integrin inhibitors
JP7425757B2 (ja) 非分岐リンカーを伴うアミノ酸化合物およびその使用方法
JP7579805B2 (ja) アミノ酸化合物の剤形およびレジメン
KR102787602B1 (ko) 아미노산 화합물 및 사용 방법
JP6530764B2 (ja) ＲＯＲγ調節因子としてのピロリジニルスルホン誘導体およびその使用
CA3042710A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
JP2005535659A (ja) 嘔吐、抑鬱、不安および咳の処置のためのニューロキニン−１（ｎｋ−１）アンタゴニストとしての１−アミド−４−フェニル−４−ベンジルオキシメチル−ピペリジン誘導体および関連化合物
AU2018326497A1 (en) Spirocycle compounds and methods of making and using same
CA2953885A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
AU2022265730A1 (en) Expanded dosage regimens for integrin inhibitors
CN106928113B (zh) 组织蛋白酶k抑制剂及其用途
BR122023025996A2 (pt) Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção
HK40057175A (en) Amino acid compounds and methods of use
HK40049583A (en) Amino acid compounds with unbranched linkers and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240716

R150 Certificate of patent or registration of utility model

Ref document number: 7523450

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150